Starling Oncology (STLN) Stock Analysis & Winston Score
Starling Oncology, Inc. is a healthcare company focused on cancer care. It operates or manages oncology treatment facilities where patients receive services like chemotherapy, radiation, and related cancer therapies. The company works within the broader medical care facilities industry, serving cancer patients primarily through clinic-based settings and partnering with oncologists and health systems to deliver treatment. The company generates revenue by providing cancer treatment services, typically billing insurance companies, Medicare, Medicaid, and patients directly for care delivered at its facilities. Starling Oncology appears to operate primarily in the United States, and like many specialty care providers, its competitive position depends on relationships with referring physicians and contracts with major insurers. The key growth opportunity lies in expanding its network of cancer care locations as demand for oncology services rises with an aging population, though reimbursement rate pressures from government and private payers remain a significant ongoing risk to profitability.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Data not available (0/30)
- Growth: Data not available (0/20)
- Cash Flow: Data not available (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Ownership data not available (not counted) (0/15)
Key Facts
Price: $6.41
Market Cap: $641M
Sector: Healthcare
Industry: Medical - Care Facilities
Exchange: NASDAQ
